Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
作者信息
Souchet Benoit, Audrain Mickael, Billoir Baptiste, Lecanu Laurent, Tada Satoru, Braudeau Jérôme
机构信息
AgenT, 4 rue Pierre-Fontaine, 91058 EVRY Cedex, France.
出版信息
Neural Regen Res. 2018 Feb;13(2):224-225. doi: 10.4103/1673-5374.226389.
Abstract
摘要
相似文献
1
Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?是时候通过针对阿尔茨海默病的无症状阶段来重新思考其药物研发策略了吗？
Neural Regen Res. 2018 Feb;13(2):224-225. doi: 10.4103/1673-5374.226389.
2
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.FUNDAMANT：一项针对 AADvac1 的干预性 72 周 1 期随访研究，AADvac1 是一种针对阿尔茨海默病tau 蛋白病理学的主动免疫疗法。
Alzheimers Res Ther. 2018 Oct 24;10(1):108. doi: 10.1186/s13195-018-0436-1.
3
Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders.支链氨基酸代谢在阿尔茨海默病及其他代谢紊乱发展中的作用。
Neural Regen Res. 2020 Aug;15(8):1460-1470. doi: 10.4103/1673-5374.274328.
4
Natural Products based P-glycoprotein Activators for Improved β-amyloid Clearance in Alzheimer's Disease: An in silico Approach.基于天然产物的P-糖蛋白激活剂用于改善阿尔茨海默病中的β-淀粉样蛋白清除：一种计算机模拟方法。
Cent Nerv Syst Agents Med Chem. 2015;16(1):50-9. doi: 10.2174/1871524915666150826092152.
5
Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease.阿尔茨海默病中与β淀粉样蛋白相关治疗策略的发展进展
Drug News Perspect. 2002 Mar;15(2):102-109. doi: 10.1358/dnp.2002.15.2.668336.
6
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.对集落刺激因子1受体（CSF1R）进行药物靶向治疗可抑制小胶质细胞增殖，并预防阿尔茨海默病样病理进程。
Brain. 2016 Mar;139(Pt 3):891-907. doi: 10.1093/brain/awv379. Epub 2016 Jan 8.
7
Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?谷氨酰胺环化酶的小分子抑制剂能否用作阿尔茨海默病的治疗药物？
Future Med Chem. 2017 Nov;9(17):1979-1981. doi: 10.4155/fmc-2017-0190. Epub 2017 Oct 27.
8
Vascular aspects in Alzheimer's disease.阿尔茨海默病中的血管方面
J Neural Transm Suppl. 2000;59:37-43. doi: 10.1007/978-3-7091-6781-6_6.
9
Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.纳米颗粒包裹的他仑氟比治疗药物的鼻内给药：一种针对阿尔茨海默病的潜在脑靶向策略。
Eur J Pharm Sci. 2016 Sep 20;92:224-34. doi: 10.1016/j.ejps.2016.05.012. Epub 2016 May 14.
10
Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease.用于检测临床前阿尔茨海默病的脑脊液生物标志物的最新进展。
Curr Opin Neurol. 2016 Dec;29(6):749-755. doi: 10.1097/WCO.0000000000000399.
引用本文的文献
1
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study.多组学生物标志物在一项多中心队列研究中以高特异性预测阿尔茨海默病前驱期。
J Prev Alzheimers Dis. 2024;11(3):567-581. doi: 10.14283/jpad.2024.34.
2
Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?基于淀粉样蛋白状态的阿尔茨海默病的生物学诊断：医学研究中确认偏倚的例证？
Int J Mol Sci. 2023 Dec 16;24(24):17544. doi: 10.3390/ijms242417544.
3
The Interplay Between Beta-Amyloid 1-42 (Aβ)-Induced Hippocampal Inflammatory Response, p-tau, Vascular Pathology, and Their Synergistic Contributions to Neuronal Death and Behavioral Deficits.β-淀粉样蛋白1-42（Aβ）诱导的海马炎症反应、磷酸化tau蛋白、血管病理之间的相互作用及其对神经元死亡和行为缺陷的协同作用。
Front Mol Neurosci. 2020 Nov 2;13:522073. doi: 10.3389/fnmol.2020.552073. eCollection 2020.
4
Yizhiqingxin Formula Alleviates Cognitive Deficits and Enhances Autophagy mTOR Signaling Pathway Modulation in Early Onset Alzheimer's Disease Mice.益智清心方改善早发性阿尔茨海默病小鼠的认知缺陷并增强自噬 mTOR 信号通路调控
Front Pharmacol. 2019 Sep 17;10:1041. doi: 10.3389/fphar.2019.01041. eCollection 2019.
本文引用的文献
1
Alzheimer's disease drug development pipeline: 2017.2017年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2017 May 24;3(3):367-384. doi: 10.1016/j.trci.2017.05.002. eCollection 2017 Sep.
2
βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease.βAPP 处理驱动阿尔茨海默病的年龄依赖淀粉样模型中的渐增 Tau 病理学。
Cereb Cortex. 2018 Nov 1;28(11):3976-3993. doi: 10.1093/cercor/bhx260.
3
LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent.细胞外淀粉样前体蛋白（Aβ）和 Tau 寡聚体引起的长时程增强（LTP）和记忆损伤是由淀粉样前体蛋白（APP）依赖的。
Elife. 2017 Jul 11;6:e26991. doi: 10.7554/eLife.26991.
4
Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression.野生型小鼠中类似阿尔茨海默病的淀粉样前体蛋白加工过程将突触缺陷确定为疾病进展的初始步骤。
Mol Neurodegener. 2016 Jan 12;11:5. doi: 10.1186/s13024-016-0070-y.
5
Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.在阿尔茨海默病痴呆临床诊断前18年出现认知障碍。
Neurology. 2015 Sep 8;85(10):898-904. doi: 10.1212/WNL.0000000000001774. Epub 2015 Jun 24.
6
Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains.散发性阿尔茨海默病大脑单个神经元中淀粉样前体蛋白（APP）基因拷贝数增加的基因组镶嵌现象。
Elife. 2015 Feb 4;4:e05116. doi: 10.7554/eLife.05116.
7
The evolution of preclinical Alzheimer's disease: implications for prevention trials.临床前阿尔茨海默病的演变：对预防试验的启示。
Neuron. 2014 Nov 5;84(3):608-22. doi: 10.1016/j.neuron.2014.10.038.
8
Modeling Alzheimer's disease with non-transgenic rat models.用非转基因大鼠模型模拟阿尔茨海默病。
Alzheimers Res Ther. 2013 May 1;5(3):17. doi: 10.1186/alzrt171. eCollection 2013.
9
Out-of-pocket spending in the last five years of life.生命最后五年的自付支出。
J Gen Intern Med. 2013 Feb;28(2):304-9. doi: 10.1007/s11606-012-2199-x. Epub 2012 Sep 5.
10
Alzheimer disease models and human neuropathology: similarities and differences.阿尔茨海默病模型与人类神经病理学：异同点
Acta Neuropathol. 2008 Jan;115(1):5-38. doi: 10.1007/s00401-007-0312-8. Epub 2007 Nov 16.
Zotero 插件